Cite
HARVARD Citation
Koshino, A. et al. (2023). Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Diabetes, obesity & metabolism. 25 (5), pp. 1413-1418. [Online].